Phase 2 Trial of Neoadjuvant Durvalumab and Tremelimumab with Chemotherapy Does Not Meet Primary Endpoint in Advanced High-Grade Serous Ovarian Cancer
A phase 2 trial found that adding immunotherapy to chemotherapy did not improve the primary efficacy endpoint in advanced ovarian ...
